Every Form 4 that Mesa Laboratories Inc (MLAB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MLAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MLAB filings page.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Capone Mark Christopher reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Mark Christopher Capone received a grant of 2,423 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of the company’s common stock and is scheduled to vest on September 9, 2027. Following this award, he holds 2,423 RSUs directly. No Rule 10b5-1 trading plan is reported.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Ladiwala Shiraz Shabanali reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Shiraz Shabanali Ladiwala received a grant of 2,510 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of common stock and vests on September 9, 2027. Following this grant, Ladiwala holds 2,510 RSUs directly, and no Rule 10b5-1 trading plan is reported.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Alltoft Jennifer Sadie reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Jennifer Sadie Alltoft received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2009. Each RSU represents a contingent right to receive one share of common stock and vests on September 9, 2027. After this award, she holds 1,774 RSUs directly, and no Rule 10b5-1 plan is reported.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Hall Shannon reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Shannon Hall received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of common stock and is scheduled to vest on September 9, 2027, resulting in direct ownership of 1,774 RSUs following the award.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Sullivan John James reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director John James Sullivan received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of common stock and is scheduled to vest on September 9, 2027, resulting in direct holdings of 1,774 RSUs.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Tripeny R Tony reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director R. Tony Tripeny received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of Mesa Laboratories common stock and vests on September 9, 2027. Following this award, the reporting person holds 1,774 RSUs directly. No transactions were made under a Rule 10b5-1 trading plan.
Mesa Laboratories director Mark Christopher Capone reported the vesting and exercise of 2,784 Restricted Stock Units into an equal number of shares of common stock on August 15, 2026. The derivative RSU position was reduced to zero in this transaction, and his directly held common stock position increased to 6,213 shares.
Mesa Laboratories director Jennifer Sadie Alltoft reported the vesting and settlement of 2,784 Restricted Stock Units (RSUs) into common stock of Mesa Laboratories Inc. Each RSU represented one share of common stock and vested on August 15, 2026. On that date, 2,784 RSUs were exercised and disposed of as derivatives, and 2,784 shares of common stock were acquired at a stated price of $0.00 per share. Following these transactions, Alltoft directly held 7,662 shares of common stock and had no remaining holdings in the reported RSU award. The filing’s Rule 10b5-1 checkbox was not marked as being under a trading plan.
For MESA LABORATORIES INC (MLAB), director Shiraz Shabanali Ladiwala reported the vesting and settlement of 3,810 Restricted Stock Units (RSUs) on August 15, 2026. The RSUs, each representing a contingent right to one share of common stock, were exercised at $0.00 per share, converting into 3,810 shares of common stock. Following this transaction, Ladiwala directly holds 12,333 shares of MLAB common stock.
Mesa Laboratories, Inc. (MLAB) director Shannon Hall reported the vesting and settlement of 2,784 Restricted Stock Units into an equal number of shares of common stock on August 15, 2026. The derivative RSU position was reduced to zero, and Hall now directly holds 6,973 shares of common stock.
Mesa Laboratories director R. Tony Tripeny reported the vesting and settlement of 2,784 Restricted Stock Units (RSUs) into 2,784 shares of common stock on August 15, 2026. The RSUs, each representing a contingent right to one common share, vested on that date, increasing his directly held common stock to 9,082 shares. The derivative RSU position was reduced to zero as a result of this exercise and conversion.
Mesa Laboratories director John James Sullivan reported the vesting and settlement of 2,784 Restricted Stock Units, each converting into one share of common stock at $0.00 per share, on August 15, 2026. This exercise eliminated the RSU balance and increased his directly held common stock to 20,618 shares. He is also reported as having 45,110 shares of common stock held indirectly by the “Sullivan Family Trust,” for which his spouse serves as trustee, and he disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest.
Mesa Laboratories director John James Sullivan reported selling 7,093 shares of common stock of MLAB on 2026-08-13 at $112.80 per share in a private transaction to President and CEO Siddhartha Kadia. After this sale, Sullivan directly holds 17,834 shares and is also reported as having an indirect interest in 45,110 shares held by the Sullivan Family Trust, for which his spouse is trustee; he disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest.
Mesa Laboratories (MLAB) President and CEO Siddhartha Kadia reported that the Anjou Parekh Lifetime Access Trust, for which his spouse serves as trustee, purchased 7,093 shares of Common Stock at $112.80 per share in a private transaction from Board Chair John Sullivan. The trust now holds 7,093 shares, reported as indirect ownership. Kadia disclaims beneficial ownership of the trust’s shares except to the extent of his pecuniary interest. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Mesa Laboratories Inc. director R. Tony Tripeny reported an open-market purchase of 900 shares of the company’s common stock on 2026-08-13 at a price of $113.69 per share. Following this transaction, Tripeny’s directly held stake increased to 6,298 shares of common stock.
Mesa Laboratories CAO Lyndsey Elizabeth Crennen reported a mix of equity compensation events and a small tax-related share sale. On June 18, 2026, she exercised restricted stock units and performance share units for a total of 726 shares of common stock and received a 263-share grant, all as direct holdings. A subsequent sale of 442 shares of common stock on June 22, 2026 at $89.502 per share was executed to cover taxes related to the June 18, 2026 vesting of RSUs and PSUs and occurred under a 10b-1 plan, according to the footnotes. Following these transactions, she directly holds 2,020 shares of Mesa Laboratories common stock.
Mesa Laboratories senior vice president of operations Brian David Archbold reported a mix of stock compensation activity and a modest sale of common shares. On June 18, 2026, he received a grant or award of 1,859 shares of common stock and exercised restricted stock units (RSUs) covering a total of 3,324 shares, converting them into common stock at a stated price of $95.10 per share for reporting purposes. Related RSU entries show derivative positions being fully converted into common stock.
On June 22, 2026, Archbold executed an open-market sale of 2,516 shares of Mesa Laboratories common stock at an average price of about $89.50 per share. After these transactions, he directly holds 6,377 common shares, indicating that a portion of the newly acquired stock was retained while some was sold for liquidity.
Mesa Laboratories CFO John Sakys reported multiple equity transactions in Mesa Laboratories common stock. On June 18, 2026, he received a grant of 2,282 shares of common stock and exercised restricted stock units (RSUs) that converted into 2,756 and 1,036 shares of common stock.
On June 22, 2026, he sold 2,827 shares at an average price of $89.502 per share. A footnote states these shares were sold to cover taxes related to the vesting of RSUs and performance share units on June 18, 2026, and that the transaction was executed under a Rule 10b5-1 trading plan.
After these transactions, Sakys held 19,785 Mesa Laboratories shares directly, plus 50 shares indirectly as custodian for his children.
Mesa Laboratories senior vice president of operations Brian David Archbold reported an open-market sale of company stock. On June 16, 2026, he sold 1,151 shares of Mesa Laboratories common stock at an average price of $101.267 per share. After this transaction, he continues to hold 3,710 shares directly.
Mesa Laboratories Chief Accounting Officer Lyndsey Elizabeth Crennen reported an open-market sale of common stock. On June 16, 2026, she sold 118 shares of Mesa Laboratories common stock at an average price of $101.267 per share. According to the footnote, the shares were sold to cover taxes due on restricted stock units (RSUs) that vested on June 15, 2026, indicating a tax-related transaction rather than a discretionary portfolio move. Following this sale, Crennen directly holds 1,473 shares of Mesa Laboratories common stock.
Mesa Laboratories CFO John Sakys reported an insider transaction involving company common stock. On June 16, 2026, he sold 1,223 shares in an open-market sale at $101.267 per share to cover taxes arising from the vesting of restricted stock units on June 15, 2026. After this sale, he directly holds 16,538 Mesa Laboratories shares. In addition, 50 shares are held indirectly for his children, where he acts as custodian.
Mesa Laboratories executive Brian David Archbold reported compensation-related equity changes. On June 15, 2026, he exercised derivative awards to acquire 2,454 shares of Mesa Laboratories common stock at $104.08 per share, increasing his direct common stock holdings to 4,861 shares.
He also received a new grant of 4,328 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in stages starting on June 15, 2026. In addition, 1,780 Non Qualified Stock Options with a $226.72 exercise price reached expiration.
Following these transactions, Archbold holds 4,328 RSUs and 11,852 Non Qualified Stock Options alongside his common shares, reflecting ongoing equity-based compensation rather than open-market buying or selling.
Mesa Laboratories CFO John Sakys reported compensation-related equity changes. He exercised derivative awards to acquire 2,717 shares of common stock, bringing his direct holdings to 17,761 shares. He also received a grant of 8,416 restricted stock units, each representing one future share of common stock.
In addition, 3,951 non-qualified stock options with a $226.72 exercise price reached expiration. Sakys also reports 50 shares of common stock held indirectly as custodian for his children.
Mesa Laboratories President and CEO Siddhartha Kadia received a grant of restricted stock units that can convert into 35,236 shares of common stock. The award was recorded at a price of $0.00 per unit as a stock-based compensation grant. Each RSU represents a right to receive one share of common stock and is scheduled to vest in three equal installments, with one-third vesting on each anniversary date of the grant. Following this award, Kadia is reported as directly holding 35,236 RSUs tied to common stock.
Kadia Siddhartha reported acquisition or exercise transactions in this Form 4 filing.
Mesa Laboratories reported that President and CEO Siddhartha Kadia received a grant of 34,807 Restricted Stock Units (RSUs) linked to the company’s common stock. Each RSU represents a contingent right to receive one share of common stock.
The RSUs vest in thirds, with 1/3 of the award vesting on each anniversary date, aligning the CEO’s compensation with longer-term company performance. Following this grant, the filing shows 34,807 RSUs held directly by the CEO, and no remaining derivative positions are listed in this report.
Mesa Laboratories President and CEO Gary M. Owens reported the expiration and forfeiture of 8,211 restricted stock units, each representing one share of common stock. The RSUs were due to vest on June 15, 2028, but were deemed expired on March 31, 2026 and returned to the issuer rather than sold on the market. Following this disposition to the company, Owens holds 16,448 restricted stock units directly.
Mesa Laboratories director Shiraz Shabanali Ladiwala reported an open-market purchase of 3,500 shares of Mesa Laboratories common stock at $72.23 per share. This buy on March 10, 2026 increased his directly held position to 8,523 shares, signaling a larger personal stake in the company.
Mesa Laboratories director Mark Christopher Capone bought additional company stock in an open-market transaction. He purchased 1,301 shares of Common Stock at a price of $76.35 per share. After this purchase, he directly owns 3,429 shares of Mesa Laboratories Common Stock.
Mesa Laboratories director R. Tony Tripeny bought shares of the company in the open market. He purchased 1,315 shares of Mesa Laboratories common stock at a price of $76.00 per share. After this transaction, his direct ownership increased to 5,398 common shares.
Mesa Laboratories Inc. director reports a gift of company stock. A Form 4 filing shows that on 12/02/2025, the reporting director disposed of 2,000 shares of Mesa Laboratories common stock in a transaction coded "G," which indicates a gift, at a reported price of $0.
Following this transaction, the director beneficially owns 25,282 shares directly and 44,780 shares indirectly through a spousal lifetime access trust. The filing notes that the indirectly held shares are owned by a trust for a spouse’s benefit, which the director reports as indirect beneficial ownership.
Mesa Laboratories (MLAB) reported an insider equity change: the President and CEO acquired 11,558 shares of common stock on 10/27/2025 via a transaction coded M, reflecting settlement of performance share units at a reported price of $0.
Following this transaction, the officer directly holds 64,135 shares. The shares relate to performance share units granted on 10/28/2021 as a special award intended to encourage continued performance and long-term retention, vesting one-third on 10/27/2024 and on each of the next two anniversary dates.